ESR1 and breast carcinoma: Therapies designed to activate PANoptosis have shown potential in preclinical models and are under exploration for refractory tumors such as triple‐negative breast cancer (TNBC), a refractory subtype of breast cancer (BCa) that lacks expression of estrogen receptor (ER), progesterone receptor, and human epidermal growth factor receptor 2 (HER2) [13, 14].